Rational polytherapy with antiepileptic drugs

Pharmaceuticals

Volumn 3, Issue 8, 2010, Pages 2362-2379

  Lee, Jong Woo ^a   Dworetzky, Barbara ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antiepileptic drug; Epilepsy; Rational polytherapy

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL; CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; GLUTAMIC ACID; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; RUFINAMIDE; SODIUM CHANNEL; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ARTICLE; CLINICAL TRIAL; COMORBIDITY; DISEASE CONTROL; DISEASE MODEL; DROWSINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG WITHDRAWAL; EPILEPSY; HUMAN; HYPONATREMIA; INDIVIDUALIZATION; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 77955586367     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3082362     Document Type: Article

References (82)

1. Reynolds, E.H.; Shorvon, S.D. Monotherapy or polytherapy for epilepsy? Epilepsia 1981, 22, 1-10.
2. Shorvon, S.D.; Chadwick, D.; Galbraith, A.W.; Reynolds, E.H. One drug for epilepsy. Br. Med. J. 1978, 1, 474-476.
3. Kwan, P.; Brodie, M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 2000, 342, 314-319.
4. Kwan, P.; Brodie, M.J. Combination therapy in epilepsy: when and what to use. Drugs 2006, 66, 1817-1829.
5. Bourgeois, B.F. Pharmacodynamic principles and mechanisms of drug interactions. In Antiepileptic drugs: Combination therapy and interactions, Majkowski, J. Bourgeois, B.F. Patsalos, P. N. Matagne, A. Eds. Cambridge University Press: Cambridge, London, UK, 2005.
6. Uijl, S.G.; Uiterwaal, C.S.; Aldenkamp, A.P.; Carpay, J.A.; Doelman, J.C.; Keizer, K.; Vecht, C.J.; de Krom, M.C.; van Donselaar, C.A. A cross-sectional study of subjective complaints in patients with epilepsy who seem to be well-controlled with anti-epileptic drugs. Seizure 2006, 15, 242-248.
7. Gilliam, F.G.; Fessler, A.J.; Baker, G.; Vahle, V.; Carter, J.; Attarian, H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 2004, 62, 23-27.
8. Pack, A.M.; Morrell, M.J. Epilepsy and bone health in adults. Epilepsy Behav. 2004, 5 (Suppl. 2), S24-S29.
9. Levy, R.H.; Mattson, R.H.; Meldrum, B.S.; Perucca, E. Antiepileptic Drugs, 5th ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2002.
10. Rogawski, M.A.; Loscher, W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci. 2004, 5, 553-564.
11. Stafstrom, C.E. Mechanisms of action of antiepileptic drugs: the search for synergy. Curr. Opin. Neurol. 2007, 23, 157-163.
12. Bianchi, M.T.; Pathmanathan, J.; Cash, S.S. From ion channels to complex networks: magic bullet versus magic shotgun approaches to anticonvulsant pharmacotherapy. Med. Hypotheses 2009, 72, 297-305.
13. Cereghino, J.J.; Brock, J.T.; Van Meter, J.C.; Penry, J.K.; Smith, L.D.; White, B.G. The efficacy of carbamazepine combinations in epilepsy. Clin. Pharmacol. Ther. 1975, 18, 733-741.
14. Jonker, D.M.; Voskuyl, R.A.; Danhof, M. Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments? Epilepsia 2007, 48, 412-434.
15. Kaminski, R.M.; Matagne, A.; Patsalos, P.N.; Klitgaard, H. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. Epilepsia 2009, 50, 387-397.
16. Fueta, Y.; Kunugita, N.; Schwarz, W. Antiepileptic action induced by a combination of vigabatrin and tiagabine. Neuroscience 2005, 132, 335-345.
17. Leach, J.P.; Brodie, M.J. Synergism with GABAergic drugs in refractory epilepsy. Lancet 1994, 343, 1650.
18. Barcs, G.; Walker, E.B.; Elger, C.E.; Scaramelli, A.; Stefan, H.; Sturm, Y.; Moore, A.; Flesch, G.; Kramer, L.; D'Souza, J. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000, 41, 1597-1607.
19. Elger, C.E.; Brodie, M.J.; Anhut, H.; Lee, C.M.; Barrett, J.A. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 2005, 46, 1926-1936.
20. Beydoun, A.; Uthman, B.M.; Kugler, A.R.; Greiner, M.J.; Knapp, L.E.; Garofalo, E.A. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005, 64, 475-480.
21. French, J.A.; Faught, E. Rational polytherapy. Epilepsia 2009, 50 (Suppl. 8), 63-68.
22. Duncan, J.S.; Shorvon, S.D.; Trimble, M.R. Effects of removal of phenytoin, carbamazepine, and valproate on cognitive function. Epilepsia 1990, 31, 584-591.
23. Campillos, M.; Kuhn, M.; Gavin, A.C.; Jensen, L.J.; Bork, P. Drug target identification using side-effect similarity. Science 2008, 321, 263-266.
24. Sabroe, T.P.; Sabers, A. Progressive anticonvulsant hypersensitivity syndrome associated with change of drug product. Acta Neurol. Scand. 2008, 117, 428-431.
25. Wojda, E.; Wlaz, A.; Patsalos, P.N.; Luszczki, J.J. Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model. Epilepsy Res. 2009, 86, 163-174.
26. Tallarida, R. J. An overview of drug combination analysis with isobolograms. J. Pharmacol. Exp. Ther. 2006, 319, 1-7.
27. Dudra-Jastrzebska, M.; Andres-Mach, M.M.; Ratnaraj, N.; Patsalos, P.N.; Czuczwar, S.J.; Luszczki, J.J. Isobolographic characterization of the anticonvulsant interaction profiles of levetiracetam in combination with clonazepam, ethosuximide, phenobarbital and valproate in the mouse pentylenetetrazole-induced seizure model. Seizure 2009, 18, 607-614.
28. Luszczki, J.J.; Andres, M.M.; Czuczwar, S.J. Synergistic interaction of gabapentin and oxcarbazepine in the mouse maximal electroshock seizure model--an isobolographic analysis. Eur. J. Pharmacol. 2005, 515, 54-61.
29. Luszczki, J.J.; Andres, M.M.; Czuczwar, P.; Cioczek-Czuczwar, A.; Ratnaraj, N.; Patsalos, P.N.; Czuczwar, S.J. Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis. Epilepsia 2006, 47, 10-20.
30. Borowicz, K.K.; Swiader, M.; Luszczki, J.; Czuczwar, S.J. Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis. Epilepsia 2002, 43, 956-963.
31. Czuczwar, S.J.; Kaplanski, J.; Swiderska-Dziewit, G.; Gergont, A.; Kroczka, S.; Kacinski, M. Pharmacodynamic interactions between antiepileptic drugs: preclinical data based on isobolography. Expert Opin. Drug Metab. Toxicol. 2009. 5, 131-136
32. Bourgeois, B.F. Anticonvulsant potency and neurotoxicity of valproate alone and in combination with carbamazepine or phenobarbital. Clin. Neuropharmacol. 1988, 11, 348-359.
33. Luszczki, J.J.; Borowicz, K.K.; Swiader, M.; Czuczwar, S.J. Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003, 44, 489-499.
34. Bourgeois, B.F. Combination of valproate and ethosuximide: antiepileptic and neurotoxic interaction. J. Pharmacol. Exp. Ther. 1988, 247, 1128-1132.
35. Luszczki, J.J.; Andres-Mach, M.M.; Ratnaraj, N.; Patsalos, P.N.; Czuczwar, S.J. Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model. Epilepsia 2007, 48, 806-815.
36. Luszczki, J.J.; Czuczwar, S.J. Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis. Eur. Neuropsychopharmacol 2005, 15, 133-142.
37. Luszczki, J.J.; Czuczwar, S.J. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia 2004, 45, 895-907.
38. Dudra-Jastrzebska, M.; Andres-Mach, M.M.; Sielski, M.; Ratnaraj, N.; Patsalos, P.N.; Czuczwar, S.J.; Luszczki, J.J. Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis. Eur. J. Pharmacol. 2009, 605, 87-94.
39. Luszczki, J.J.; Czuczwar, S.J. Isobolographic characterisation of interactions among selected newer antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model. Naunyn Schmiedebergs Arch. Pharmacol. 2005, 372, 41-54.
40. Luszczki, J.J.; Swiader, M.; Parada-Turska, J.; Czuczwar, S.J. Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice. Neuropsychopharmacology 2003, 28, 1817-1830.
41. Luszczki, J.J.; Czuczwar, S.J. Gabapentin synergistically interacts with topiramate in the mouse maximal electroshock seizure model: an isobolographic analysis. Pharmacol. Rep. 2006, 58, 944-954.
42. Luszczki, J.J.; Ratnaraj, N.; Patsalos, P.N.; Czuczwar, S.J. Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy. Eur. J. Pharmacol. 2008, 595, 13-21.
43. Luszczki, J.J.; Czuczwar, M.; Kis, J.; Krysa, J.; Pasztelan, I.; Swiader, M.; Czuczwar, S.J. Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003, 44, 1003-1013.
44. Masuda, Y.; Utsui, Y.; Shiraishi, Y.; Karasawa, T.; Yoshida, K.; Shimizu, M. Evidence for a synergistic interaction between phenytoin and phenobarbital in experimental animals. J. Pharmacol. Exp. Ther. 1981, 217, 805-811.
45. Luszczki, J.J.; Czuczwar, S.J. Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31, 529-538.
46. Luszczki, J.; Swiader, M.; Czuczwar, M.; Kis, J.; Czuczwar, S.J. Interactions of tiagabine with some antiepileptics in the maximal electroshock in mice. Pharmacol. Biochem. Behav. 2003, 75, 319-327.
47. Borowicz, K.K.; Luszczki, J.J.; Czuczwar, S.J. Isobolographic and subthreshold analysis of interactions among felbamate and four conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice. Epilepsia 2004, 45, 1176-1183.
48. Deckers, C.L.; Hekster, Y.A.; Keyser, A.; van Lier, H.J.; Meinardi, H.; Renier, W.O. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia 2001, 42, 1387-1394.
49. Carpay, J.A.; Aldenkamp, A.P.; van Donselaar, C.A. Complaints associated with the use of antiepileptic drugs: results from a community-based study. Seizure 2005, 14, 198-206.
50. Beghi, E.; Gatti, G.; Tonini, C.; Ben-Menachem, E.; Chadwick, D.W.; Nikanorova, M.; Gromov, S.A.; Smith, P.E.; Specchio, L.M.; Perucca, E. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res. 2003, 57, 1-13.
51. Kwan, P.; Brodie, M.J. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000, 9, 464-468.
52. Stephen, L.J.; Brodie, M.J. Seizure freedom with more than one antiepileptic drug. Seizure 2002, 11, 349-351.
53. Besag, F.M.; Berry, D.J.; Pool, F.; Newbery, J.E.; Subel, B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998, 39, 183-187.
54. Gidal, B.E.; Rutecki, P.; Shaw, R.; Maly, M.M.; Collins, D.M.; Pitterle, M.E. Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy. Epilepsy Res. 1997, 28, 207-211.
55. Eriksson, A.S.; Boreus, L.O. No increase in carbamazepine-10,11-epoxide during addition of lamotrigine treatment in children. Ther. Drug Monit. 1997, 19, 499-501.
56. Warner, T.; Patsalos, P.N.; Prevett, M.; Elyas, A.A.; Duncan, J.S. Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide. Epilepsy Res. 1992, 11, 147-150.
57. Landmark, C.J.; Rytter, E.; Johannessen, S.I. Clinical use of antiepileptic drugs at a referral centre for epilepsy. Seizure 2007, 16, 356-364.
58. Welty, T.; Elgavish, R.; Faught, E.; Barnes, B. Identification of potentially effective antiepileptic drug combinations in patients with epilepsy. Epilepsia 2009, 50, 94.
59. Brodie, M.J.; Yuen, A.W. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res. 1997, 26, 423-432.
60. Pisani, F.; Oteri, G.; Russo, M.F.; Di Perri, R.; Perucca, E.; Richens, A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999, 40, 1141-1146.
61. Morris, R.G.; Black, A.B.; Lam, E.; Westley, I.S. Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage? Ther. Drug Monit. 2000, 22, 656-660.
62. Panayiotopoulos, C.P.; Ferrie, C.D.; Knott, C.; Robinson, R.O. Interaction of lamotrigine with sodium valproate. Lancet 1993, 341, 445.
63. Ferrie, C.D.; Panayiotopoulos, C.P. Therapeutic interaction of lamotrigine and sodium valproate in intractable myoclonic epilepsy. Seizure 1994, 3, 157-159.
64. Rowan, A.J.; Meijer, J.W.; de Beer-Pawlikowski, N.; van der Geest, P.; Meinardi, H. Valproate-ethosuximide combination therapy for refractory absence seizures. Arch. Neurol. 1983, 40, 797-802.
65. Bourgeois, B.F. Antiepileptic drug combinations and experimental background: the case of phenobarbital and phenytoin. Naunyn Schmiedebergs Arch. Pharmacol. 1986, 333, 406-411.
66. Harden, C.L.; Zisfein, J.; Atos-Radzion, C.E.; Tuchman, A.J. Combination valproate-carbamazepine therapy in partial epilepsies resistant to carbamazepine monotherapy. J. Epilepsy 1993, 6, 91-94.
67. Stolarek, I.; Blacklaw, J.; Forrest, G.; Brodie, M.J. Vigabatrin and lamotrigine in refractory epilepsy. J. Neurol. Neurosurg. Psychiatry 1994, 57, 921-924.
68. Stephens, L.J.; Sills, G.J.; Brodie, M.J. Lamotrigine and topiramate may be a useful combination. Lancet 1998, 351, 958-959.
69. Canevini, M.P.; De Sarro, G.; Galimberti, C.A.; Gatti, G.; Licchetta, L.; Malerba, A.; Muscas, G.; La Neve, A.; Striano, P.; Perucca, E. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia 2010, 51, 797-804.
70. Wheless, J.W. Managing severe epilepsy syndromes of early childhood. J. Child Neurol. 2009, 24, 24S-32S; quiz 33S-26S.
71. Johannessen, S.I.; Tomson, T. Laboratory Monitoring of Antiepileptic Drugs. In Antiepileptic Drugs, 5th ed.; Levy, R.H., Mattson, R.H., Meldrum, B.S., Perucca, E., Eds. Lippincott, Williams & Wilkins: Philadelphia, PA, USA, 2002; pp. 104-111.
72. Perucca, E.; Kwan, P. Overtreatment in epilepsy: how it occurs and how it can be avoided. CNS Drugs 2005, 19, 897-908.
73. Harden, C.L.; Meador, K.J.; Pennell, P.B.; Hauser, W.A.; Gronseth, G.S.; French, J.A.; Wiebe, S.; Thurman, D.; Koppel, B.S.; Kaplan, P.W.; et al. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009, 50, 1237-1246.
74. Artama, M.; Auvinen, A.; Raudaskoski, T.; Isojarvi, I.; Isojarvi, J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005, 64, 1874-1878.
75. Ramsay, R.E.; Uthman, B.; Pryor, F.M.; Rowan, A.J.; Bainbridge, J.; Spitz, M.; Sirven, J.I.; Frederick, T.E. Topiramate in older patients with partial-onset seizures: a pilot double-blind, dose-comparison study. Epilepsia 2008, 49, 1180-1185.
76. Brodie, M. J.; Perucca, E.; Ryvlin, P.; Ben-Menachem, E.; Meencke, H.J. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007, 68, 402-408.
77. Mason, E.; Routledge, P.A. Combination Therapy of Diseases: General Concepts. In Antiepileptic Drugs: Combination Therapy and Interactions; Majkowski, J., Bourgeois, B.F., Patsalos, P.N., Mattson, R.H., Eds. Cambridge University Press: Cambridge, London, UK, 2005; pp. 3-15.
78. Richy, F.F.; Banerjee, S.; Brabant, Y.; Helmers, S. Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques. Epilepsy Behav. 2009, 16, 240-245.
79. Miller, A.D.; Krauss, G.L.; Hamzeh, F.M. Improved CNS tolerability following conversion from immediate to extended-release carbamazepine. Acta. Neurol. Scand. 2004, 109, 374-377.
80. Schiller, Y.; Najjar, Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 2008, 70, 54-65.
81. Wolf, P. Acute Administration of Benzodiazepines as Part of Treatment Strategies for Epilepsy. CNS Neurosci. Ther. 2010, doi:10.1111/j.1755-5949.2010.00139.x.
82. Friedman, D.; French, J.A. Effects of intermittent levetiracetam dosing in a patient with refractory daily seizures. Neurology 2006, 66, 590-591.